Update on the safety of long-acting β-agonists in combination with inhaled corticosteroids for the treatment of asthma

Annals of Allergy, Asthma and Immunology

Volumn 102, Issue 1, 2009, Pages 11-15

  Nelson, Harold S ^a   Carr, Warner ^a   Nathan, Robert ^a   Portnoy, Jay M ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL;

ADD ON THERAPY; AFRICAN AMERICAN; ARTICLE; ASTHMA; CLINICAL TRIAL; CODON; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GENOTYPE; HOMOZYGOSITY; HOSPITALIZATION; HUMAN; INHALER; LOW DRUG DOSE; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 59449087089     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60101-9     Document Type: Article

References (19)

1. Serevent and Advair [package insert]. 2003.
2. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose for moterol. Chest. 2003;124:70-74.
3. Advair [package insert]. March 2006.
4. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-20.
5. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904-912.
6. Wechsler ME, Lehman E, Lazarus SC, et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173:519-526.
7. National Heart, Lung, and Blood Institute. NHLBI Guidelines 1997. Bethesda, MD: National Heart, Lung, and Blood Institute; 1997.
8. National Heart, Lung, and Blood Institute. NHLBI Guidelines 2007. Bethesda, MD: National Heart, Lung, and Blood Institute; 2007.
9. Ernst P, Mclvor A, Ducharme FM, et al. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med. 2006;145:692-694.
10. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med. 2008;149:33-42.
11. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J. September 3, 2008. Epub ahead of print.
12. Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long acting beta agonists among patients with asthma using inhaled corticosteroids: systematic review and meta-analysis. Am J Respir Crit Care Med. September 5, 2008. Epub ahead of print.
13. Bailey W, Castro M, Matz J, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opinion. 2008;24:1669-1682.
14. Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol. 2006;118:809-816.
15. Bleecker ER, Postma DS, Lawrence RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to long acting, beta2-agonist therapy: a pharmacogenetic analysis of two randomized studies. Lancet. 2007;370:2118-2125.
16. Bleecker ER, Nelson HS, Kraft M, et al. Relationship of the beta2 adrenoceptor polymorphism at codon 16 to markers of asthma control in patients treated with fluticasone propionate plus salmeterol or salmeterol alone: results of a prospective study. In press.
17. Stanford RH, Fuhlbrigge A, Riedel A, Rey GG, Stempel DA. An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes. Curr Med Res Opinion. 2008;77:1-8.
18. Wang M-T, Skrepnek GH, Armstrong E, et al. Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma. Curr Med Res Opinion. 2008;24:859-867.
19. DiSantostefano RL, Davis KJ, Yancey S, Crim C. Ecologic analysis of asthma-related evens and dispensing of inhaled corticosteroid- and sal- meterol-containing products. Ann Allergy Asthma Immunol. 2008;100:558 -565.